SCHEMBL830354

SCHEMBL830354

Cc1ccc2cc(OC(=O)N3CCc4ccccc43)ccc2n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.52
NPSR1 Q6W5P4 2/20 0.52
ALDH1A1 P00352 3/20 0.50
USP2 O75604 1/20 0.50
MAPT P10636 4/20 0.49
KDM4E B2RXH2 1/20 0.49
POLB P06746 1/20 0.49
RAB9A P51151 10/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
TSHR P16473 3/20 0.47
GAA P10253 1/20 0.47
NPC1 O15118 6/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
NOTUM Q6P988 1/20 0.46
PKM P14618 1/20 0.45
NFKB1 P19838 1/20 0.45
MAOB P27338 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL829754 0.93 SMN1; SMN2 (0.50) LMNAALDH1A1MAPTMEN1KMT2A
SCHEMBL829224 0.83 ACHE (0.48) NPSR1ALDH1A1MAPTKDM4ERAB9A
SCHEMBL830461 0.77 SMN1; SMN2 (0.51) LMNAALDH1A1MAPTKDM4ERAB9A
SCHEMBL828658 0.77 SMN1; SMN2 (0.65) LMNANPSR1ALDH1A1MAPTPOLB
SCHEMBL14156442 0.76 RAB9A (0.62) LMNANPSR1ALDH1A1MAPTRAB9A
SCHEMBL829646 0.76 SMN1; SMN2 (0.68) LMNANPSR1ALDH1A1MAPTKDM4E
SCHEMBL833986 0.75 FAAH (0.54) LMNAALDH1A1MAPTKDM4EPOLB
SCHEMBL27531930 0.74 KMT2A (0.54) ALDH1A1MAPTRAB9AMEN1KMT2A
SCHEMBL829344 0.73 GAA (0.54) LMNANPSR1ALDH1A1MAPTKDM4E
SCHEMBL7601844 0.72 ALDH1A1 (0.66) LMNAALDH1A1MAPTKDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production VEGFA, FLT4, FLT1 LMNA 4326/4885NPSR1 1239/4885ALDH1A1 936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.